WO2023049981A1 - Composição antissebogênica, formulação e uso da composição - Google Patents
Composição antissebogênica, formulação e uso da composição Download PDFInfo
- Publication number
- WO2023049981A1 WO2023049981A1 PCT/BR2022/050387 BR2022050387W WO2023049981A1 WO 2023049981 A1 WO2023049981 A1 WO 2023049981A1 BR 2022050387 W BR2022050387 W BR 2022050387W WO 2023049981 A1 WO2023049981 A1 WO 2023049981A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- weight
- composition
- acne
- glycol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 137
- 238000009472 formulation Methods 0.000 title claims description 51
- 206010000496 acne Diseases 0.000 claims abstract description 64
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 61
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 34
- 239000000194 fatty acid Substances 0.000 claims abstract description 34
- 229930195729 fatty acid Natural products 0.000 claims abstract description 34
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 33
- 229920005862 polyol Polymers 0.000 claims abstract description 26
- 150000003077 polyols Chemical class 0.000 claims abstract description 25
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 26
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 25
- 239000002537 cosmetic Substances 0.000 claims description 25
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 25
- 235000010447 xylitol Nutrition 0.000 claims description 25
- 239000000811 xylitol Substances 0.000 claims description 25
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 25
- 229960002675 xylitol Drugs 0.000 claims description 25
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 22
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 14
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 10
- 125000004122 cyclic group Chemical group 0.000 claims description 10
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 229960002446 octanoic acid Drugs 0.000 claims description 10
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 9
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 9
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 9
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- KZVAAIRBJJYZOW-VPENINKCSA-N (2r,3r,4s)-2-(hydroxymethyl)oxolane-3,4-diol Chemical compound OC[C@H]1OC[C@H](O)[C@H]1O KZVAAIRBJJYZOW-VPENINKCSA-N 0.000 claims description 5
- 229940083987 anhydroxylitol Drugs 0.000 claims description 5
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 claims description 5
- YWWVWXASSLXJHU-AATRIKPKSA-N (9E)-tetradecenoic acid Chemical compound CCCC\C=C\CCCCCCCC(O)=O YWWVWXASSLXJHU-AATRIKPKSA-N 0.000 claims description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 claims description 4
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims description 4
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 4
- 239000005639 Lauric acid Substances 0.000 claims description 4
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 3
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 235000021342 arachidonic acid Nutrition 0.000 claims description 3
- 229940114079 arachidonic acid Drugs 0.000 claims description 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- IFWQSSUUCVSCSK-UHFFFAOYSA-N 1,2-hexacosanediol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(O)CO IFWQSSUUCVSCSK-UHFFFAOYSA-N 0.000 claims description 2
- BTOOAFQCTJZDRC-UHFFFAOYSA-N 1,2-hexadecanediol Chemical compound CCCCCCCCCCCCCCC(O)CO BTOOAFQCTJZDRC-UHFFFAOYSA-N 0.000 claims description 2
- KUWCMTFKTVOJID-UHFFFAOYSA-N 1,2-icosanediol Chemical compound CCCCCCCCCCCCCCCCCCC(O)CO KUWCMTFKTVOJID-UHFFFAOYSA-N 0.000 claims description 2
- 229940043375 1,5-pentanediol Drugs 0.000 claims description 2
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 claims description 2
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 claims description 2
- CUZKCNWZBXLAJX-UHFFFAOYSA-N 2-phenylmethoxyethanol Chemical compound OCCOCC1=CC=CC=C1 CUZKCNWZBXLAJX-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 claims description 2
- 235000021357 Behenic acid Nutrition 0.000 claims description 2
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 claims description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000021314 Palmitic acid Nutrition 0.000 claims description 2
- 235000021319 Palmitoleic acid Nutrition 0.000 claims description 2
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropanol Chemical compound CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 claims description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 2
- 229940116226 behenic acid Drugs 0.000 claims description 2
- 229940015303 cetyl glycol Drugs 0.000 claims description 2
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims description 2
- 229940051250 hexylene glycol Drugs 0.000 claims description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 2
- 229960000367 inositol Drugs 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 229960004232 linoleic acid Drugs 0.000 claims description 2
- 229960004488 linolenic acid Drugs 0.000 claims description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 229960002969 oleic acid Drugs 0.000 claims description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 2
- 229950009195 phenylpropanol Drugs 0.000 claims description 2
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 claims description 2
- 229960003656 ricinoleic acid Drugs 0.000 claims description 2
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 claims description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 2
- 150000002016 disaccharides Chemical class 0.000 claims 1
- 210000002374 sebum Anatomy 0.000 abstract description 21
- 150000002334 glycols Chemical class 0.000 abstract description 12
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 239000011885 synergistic combination Substances 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 29
- 241000186427 Cutibacterium acnes Species 0.000 description 28
- 230000009467 reduction Effects 0.000 description 25
- 230000000845 anti-microbial effect Effects 0.000 description 18
- 239000004599 antimicrobial Substances 0.000 description 16
- 230000003902 lesion Effects 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 230000003110 anti-inflammatory effect Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 244000005700 microbiome Species 0.000 description 13
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 12
- 230000009471 action Effects 0.000 description 11
- 230000002757 inflammatory effect Effects 0.000 description 11
- 229940068196 placebo Drugs 0.000 description 11
- 239000000902 placebo Substances 0.000 description 11
- 150000004032 porphyrins Chemical class 0.000 description 11
- -1 hexitol anhydrides Chemical class 0.000 description 10
- 230000001530 keratinolytic effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 229940035437 1,3-propanediol Drugs 0.000 description 8
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 8
- 206010015150 Erythema Diseases 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 230000000813 microbial effect Effects 0.000 description 8
- 229940061720 alpha hydroxy acid Drugs 0.000 description 7
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000004342 Benzoyl peroxide Substances 0.000 description 6
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 235000019400 benzoyl peroxide Nutrition 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 229960004889 salicylic acid Drugs 0.000 description 6
- 229960003604 testosterone Drugs 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 230000003255 anti-acne Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 5
- 210000001732 sebaceous gland Anatomy 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000003974 emollient agent Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000000344 soap Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 125000005023 xylyl group Chemical group 0.000 description 4
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 3
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 3
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229940124091 Keratolytic Drugs 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 206010039792 Seborrhoea Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000000058 anti acne agent Substances 0.000 description 3
- 229940124340 antiacne agent Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940100524 ethylhexylglycerin Drugs 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 229940043259 farnesol Drugs 0.000 description 3
- 229930002886 farnesol Natural products 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- IHCDKJZZFOUARO-UHFFFAOYSA-M sulfacetamide sodium Chemical compound O.[Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1 IHCDKJZZFOUARO-UHFFFAOYSA-M 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010048810 Sebaceous hyperplasia Diseases 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 102000008228 Toll-like receptor 2 Human genes 0.000 description 2
- 108010060888 Toll-like receptor 2 Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000736 corneocyte Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000013020 final formulation Substances 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000000069 hyperpigmentation Diseases 0.000 description 2
- 230000003810 hyperpigmentation Effects 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- WEYVVCKOOFYHRW-UHFFFAOYSA-N usnic acid Chemical group CC12C(=O)C(C(=O)C)=C(O)C=C1OC1=C2C(O)=C(C)C(O)=C1C(C)=O WEYVVCKOOFYHRW-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- CUGDYSSBTWBKII-LXGUWJNJSA-N (2r,3r,4r,5s)-6-(dimethylamino)hexane-1,2,3,4,5-pentol Chemical compound CN(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO CUGDYSSBTWBKII-LXGUWJNJSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- KQIGMPWTAHJUMN-UHFFFAOYSA-N 3-aminopropane-1,2-diol Chemical compound NCC(O)CO KQIGMPWTAHJUMN-UHFFFAOYSA-N 0.000 description 1
- 102100034254 3-oxo-5-alpha-steroid 4-dehydrogenase 1 Human genes 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 101150076800 B2M gene Proteins 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 101100207370 Curvularia clavata TR07 gene Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 101000640855 Homo sapiens 3-oxo-5-alpha-steroid 4-dehydrogenase 1 Proteins 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241000233614 Phytophthora Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 238000012193 PureLink RNA Mini Kit Methods 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003853 activation of bipolar cell growth Effects 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- 208000009736 adult acne Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003718 aged appearance Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940071160 cocoate Drugs 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000002796 immunocontraceptive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000006759 inflammatory activation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 1
- 229940048848 lauryl glucoside Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical group O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229930195732 phytohormone Natural products 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- OJTDGPLHRSZIAV-UHFFFAOYSA-N propane-1,2-diol Chemical compound CC(O)CO.CC(O)CO OJTDGPLHRSZIAV-UHFFFAOYSA-N 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000009703 regulation of cell differentiation Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 210000004378 sebocyte Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 208000010744 skin desquamation Diseases 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229940047670 sodium acrylate Drugs 0.000 description 1
- 229940080321 sodium anisate Drugs 0.000 description 1
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 description 1
- 229940058349 sodium levulinate Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
- FWFUWXVFYKCSQA-UHFFFAOYSA-M sodium;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C FWFUWXVFYKCSQA-UHFFFAOYSA-M 0.000 description 1
- AETSDHMVQHOYPB-UHFFFAOYSA-M sodium;4-methoxybenzoate Chemical compound [Na+].COC1=CC=C(C([O-])=O)C=C1 AETSDHMVQHOYPB-UHFFFAOYSA-M 0.000 description 1
- RDKYCKDVIYTSAJ-UHFFFAOYSA-M sodium;4-oxopentanoate Chemical compound [Na+].CC(=O)CCC([O-])=O RDKYCKDVIYTSAJ-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000213 tara gum Substances 0.000 description 1
- 235000010491 tara gum Nutrition 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229940004858 usnic acid Drugs 0.000 description 1
- ICTZCAHDGHPRQR-UHFFFAOYSA-N usnic acid Natural products OC1=C(C)C(O)=C(C(C)=O)C2=C1C1(C)C(O)=C(C(=O)C)C(=O)C=C1O2 ICTZCAHDGHPRQR-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
Definitions
- the present invention describes an antisebogenic composition comprising a synergistic combination of glycols, polyols and fatty acids. Furthermore, the present invention presents the use of this composition in the control of sebum production and in the treatment of acne. The present invention lies in the fields of Pharmacy, Chemistry and Cosmetology.
- Sebum is a secretion produced by the sebaceous glands. Such secretion is formed by triglycerides, cholesterol, cholesterol esters and fatty acids, in addition to portions of the secretory cell. The function of sebum is to maintain skin hydration through the formation of a protective lipid layer which reduces fluid loss from the epidermis. Sebum also lubricates the surface of the skin and prevents hair from drying out (BOELSMA et al, 2003).
- excessive sebum production can trigger numerous conditions related to the skin and scalp, such as: increased pore size, which implies an aged appearance of the skin; sebaceous hyperplasia, a benign disorder of the sebaceous glands, which enlarge; dermatosis; seborrhea, a disease that causes scaly, red patches on the skin, especially on the scalp, and whose symptoms may include rash, dandruff, erythema. Sebum production is also directly related to the pathology of acne.
- Acne is a skin condition that affects approximately 9.4% of the world's population, ranked eighth among the most frequent skin diseases (TAN & BHATE, 2015; HENG & CHEW, 2020). Very common in teenagers, it is estimated that 85% of this public is affected by this condition which, despite decreasing with age, still has a significant prevalence in adulthood, affecting approximately up to 40% of women aged 20-40 years (HOLZMANN & SHAKERY, 2014; HENG & CHEW, 2020). Despite being more frequent in men during adolescence, this trend is reversed in cases of adult acne (KNUTSEN-LARSON et al., 2012).
- the acne condition comes from a multifactorial condition, which may involve gender, age, ethnicity, genetics, habits, etc. Basically, acne is caused by 4 processes: increased and altered sebum production, colonization of the hair follicle by Cutibacterium acnes (C. acnes - formerly known as Propionibacterium acnes), localized release of inflammatory mediators, and alteration in the keratinization process that leads to the formation of comedones (WILLIAMS et al, 2012). The order in which the events are triggered is still uncertain, but it is a fact that for acne to appear, the 4 processes must occur.
- C. acnes is an anaerobic microorganism, but oxygen tolerant, resident of the cutaneous microflora. Evidence shows that it is present in significant numbers in human skin, regardless of whether they have acne (JAPPE et al., 2002). This microorganism is predominantly found in areas rich in sebaceous glands and also close to the eccrine and mucous sweat glands, since it feeds on lipids and fatty acids, compounds produced in these regions (SHU et al., 2013), secreting porphyrins, molecules that can generate reactive oxygen species fueling the inflammatory process (PLATSIDAKI et al. 2018).
- retinoids In the treatment of acne, by topical application, the most commonly used ingredients are retinoids, benzoyl peroxide, salicylic acid, sulfur, sodium sulfacetamide and alpha hydroxy acids (AHAs) (BOWE and SHALITA, 2008; BRENNER et al. , 2012).
- Isotretinoin is a highly potent inhibitor of sebum production. This effect is believed to be linked to the induction of apoptosis in several cell types, including sebocytes in the sebaceous gland (NELSON et al, 2006). However, the list of adverse effects is wide and well known and, therefore, its use in combating skin oiliness can be considered controversial. Other retinoids, such as tretinoin and adapalene, remain as options, but they can cause skin irritation characterized by redness and scaling; in addition, its use requires medical advice (CHIEN, 2018).
- benzoyl peroxide One of the ingredients most indicated by dermatologists in cases of mild or moderate acne is benzoyl peroxide. Normally applied in lotions, creams and cleaning gels, benzoyl peroxide acts to reduce the population of C. acnes, through the generation of reactive oxygen species (ERO) in the pilosebaceous follicle. In this way, it helps in the dissolution of sebum, preventing the growth of the microorganism (SAGRANSKY et al., 2009). However, it is suggested that for the elimination of C. acnes, the application of benzoyl peroxide should be combined with a topical antibiotic (BOWE and SHALITA, 2008).
- ERO reactive oxygen species
- Salicylic acid is a phytohormone that acts in the regulation of growth and cell differentiation of the skin, promoting the desquamation of the stratum corneum, due to its chemical affinity with the intercellular cement between the corneocytes. In this way, salicylic acid reduces the stratum corneum of the skin and, consequently, unclogs the pilosebaceous follicles, increasing cell renewal (FONSECA et al., 2012).
- alpha-hydroxy acids from fruits, vegetables and milk, are weak organic acids that promote skin desquamation through intercellular ionic bonds of the epidermis, thus reducing the corneocyte cohesion. Due to their keratolytic property, AHAs are commonly indicated for the treatment of moderate to severe acne. In addition, the compound is also used for the treatment of hyperpigmentation, caused by the inflammatory processes of acne (BABILAS et al, 2012).
- Propanediol is a glycol, it can be produced from renewable resources using microorganisms. In addition to its action as a humectant for the skin, propanediol is known as a “booster 1 ' in preservation systems, presenting synergistic action with traditional preservatives in concentrations of up to 2% (COSMETIC INNOVATION, 2016).
- Xylitol a naturally occurring five-carbon polyol (sugar alcohol), is used in various products as a sugar substitute (TAKEUSHI et al., 2018). It is suggested to have beneficial effects on oral health. Chewing gum containing xylitol leads to a reduction in the number of bacteria in saliva, without changing the oral microbial composition, in addition to inhibiting the growth and metabolism of Streptococcus mutants, which is the main cause of dental caries (TAKEUSHI et al., 2018).
- Caprylic acid is a saturated fatty acid and one of the constituents of coconut and palm oil. Recently, liposomes loaded with fatty acids were found to efficiently inhibit the growth of C. acnes by directly melting into bacterial membranes and releasing acidic cargo. Thus, LIU AND HUANG (2013) conducted a study where they analyzed the inhibitory effects of fatty acids against C. acnes. The results showed that only short-chain fatty acids and stearic acid exert a slight inhibition on the growth of C. acnes.
- capric acid C10:0
- lauric acid C12:0
- caprylic acid C8:0
- concentrations of 6.9 mM 1 mg/ml_
- 8.6 mM 1 mg/ml_
- CHUA et al. compared lipopeptide-based immunocontraceptive vaccines containing different lipid chains and found that the C8:0 chain had the worst performance in activating NF-KB in a TLR receptor. -2 when compared to C18:0, C16:0, and C12:0, which is below the minimum structural requirements for optimal TLR-2 binding and subsequent NF-B signaling.
- Xylyl sesquicaprylate is a mixture of mono and diesters of caprylic acid and hexitol anhydrides derived from xylitol.
- C-8 xylitol monoester has a minimum inhibitory concentration (MIC) between 1.0% and 1.25% against Staphylococcus aureus, Escherichia coli and Candida albicans and 1.0% and 1.50% against Pseudomonas aeruginosa and Aspergillus niger.
- MIC minimum inhibitory concentration
- a preservative system challenge test was evaluated in a lotion containing 1% xylitol C-8 monoester and the result indicated that the molecule has antimicrobial activity against the microorganisms tested, being considered an alternative preservative system for use in cosmetics (AMARAL et al., 2011).
- Anhydroxylitol is a by-product of the synthesis of xylyl caprylate esters. No studies were found reporting antimicrobial activity of anhydroxylitol. There are currently no reports of specific action of anhydroxylitol against C. acnes or action in the control of sebum, keratolytic or anti-inflammatory.
- WO2012151441 NATURAL ANTIMICROBIAL COMPOSITIONS, which deals with a composition containing a combination of (a) lauric acid, (b) caprylic acid and (c) glycereth-2-cocoate or 1,3-propanediol which acts synergistically against bacteria and fungi, more specifically, S. aureus, P. aeruginosa, E.
- Candida albicans Aspergillus niger and Phytophthora ramrum and is indicated for use as a preservation system for cosmetic, pharmaceutical and food products, differing from the use of the object of this patent , which aims to be used in formulations for sebum control and/or anti-acne treatment.
- WO201 1047420 - COSMETIC COMPOSITIONS whose patent object is an anti-acne, anti-dandruff and anti-dermatitis antimicrobial composition containing (i) a polymer of 2-propenal and (ii) a C3-C10 alkanediol, including 1 , 3-propanediol, which differs from the object of this patent, both in composition and in use for sebum control.
- EP2496215 - ANTIMICROBIAL AND ANTI-ACNE FORMULATIONS in which glycols are formulation components whose main benefit-promoting active is usnic acid or derivative (usnate).
- US20180153177 BOTANICAL ANTIMICROBIAL COMPOSITIONS, in which 1,3-propanediol is part of a formulation for oral hygiene with microbial control properties, in which it helps in the solubilization of the essential oil in order to increase its antimicrobial effectiveness.
- Document US20180153177 also mentions the use of sugars, one of which is xylitol, as a possible component of the formulation for oral hygiene, but without attributing a specific function related to microbial action to it.
- Xylitol is commonly used as a sweetener in oral care formulations.
- Document US 8,716,506 B2 and KR101939851 B1 reveal the antimicrobial activities of xylitol derivatives against Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Aspergillus nigere, Candida albicans and the application as a preservative system of these molecules, associated or not with other antimicrobials. No antimicrobial effect on C. acnes is mentioned, nor a possible use as an aid in the control of acne or sebum production or anti-inflammatory or keratolytic action.
- Document EP1050300 B1 discloses a selective antimicrobial formulation for S. aureus comprising xylitol and farnesol, in which the concentration of each component is from 0.01 to 30% by weight of xylitol, and from 0.001 to 10% by weight of farnesol.
- the composition of the present patent application has lower polyol concentrations due to the synergy between the components, additionally the polyol concentration in the composition and final formulation of the present patent application are surprisingly lower.
- WO201821 1333 A1 refers to a preservative system comprising xylitol ester and/or ether, caprylyl glycol, ethylhexylglycerin, and 1,3-propanediol, in which such components may be in the final formulation in a concentration of: 0, 1-2.5% (w/w) xylitol ester and/or ether; 0.25-3.0% (w/w) caprylyl glycol; 0.1 -2% (w/w) ethylhexylglycerin; and 1.0-10.0% (w/w) 1,3-propanediol.
- a composition as defined in the present patent application disclosed, nor its use in the treatment of acne and/or control of sebogenesis.
- the present invention solves the problems of the state of the art from an antisebogenic composition comprising polyols, glycols and fatty acids, and the composition can be used to reduce the bacteria that cause acne (Cutibacterium acnes), controlling sebum production and skin oiliness and minimizing redness and inflammation associated with acne lesions.
- an antisebogenic composition comprising polyols, glycols and fatty acids
- the composition can be used to reduce the bacteria that cause acne (Cutibacterium acnes), controlling sebum production and skin oiliness and minimizing redness and inflammation associated with acne lesions.
- the present invention presents an antisebogenic composition
- an antisebogenic composition comprising: a) 10% to 50% by weight of at least one fatty acid with 3 to 22 carbons; b) 10% to 50% by weight of at least one polyol; c) 20% to 70% by weight of at least one glycol.
- the present invention presents a cosmetic and/or pharmaceutical formulation comprising from 0.1% to 5.0% by weight of said antisebogenic composition and from 0.1% to 15% of a cosmetically and /or pharmaceutically acceptable.
- the present invention presents the use of said antisebogenic composition in the preparation of a formulation for a dermatological and/or aesthetic method.
- Figure 1 shows a bar graph with the composition effects antisebogenic, in this embodiment identified as P19/7, on the expression of 5 alpha reductase type 1 in human keratinocytes, cultured after 24 hours of incubation.
- Figure 2 shows a bar graph with the percentage variation of porphyrin decrease for P19/7 applied in cosmetic base at 0.5% (w/w) or 1.0% (w/w) and base Placebo cosmetics by period (D7-D0 / D28-D0). *p ⁇ 0.05 in relation to the initial time (D0).
- Figure 3 shows images obtained by the Visia® equipment of two participants illustrating the reduction in porphyrin after 28 days of treatment with P19/7 at 0.5% and 1.0% by weight.
- Figure 4 shows a bar graph with the variation in the percentage of sebum reduction for P19/7 applied in a cosmetic base at 0.5% (w/w) or 1.0% (w/w) and base Placebo cosmetics by period (D7-D0 / D28-D0). *p ⁇ 0.05 in relation to the initial time (D0).
- Figure 5 shows a bar graph with the percentage variation of the decrease in inflammatory lesions for P19/7 applied on a cosmetic base at 0.5% (w/w) or 1 .0% (w/w) and Placebo cosmetic base per period (D7-D0 / D28-D0). *p ⁇ 0.05 in relation to the initial time (D0).
- Figure 6 shows images obtained by the Visia® equipment of two participants illustrating the decrease in inflammatory lesions after 28 days of treatment with P19/7 at 0.5% and 1.0% by weight.
- Figure 7 shows photographs of three participants illustrating the improvement in the appearance/appearance of the skin after 28 days of treatment with P 19/7 at 0.5% or 1.0% by weight.
- the formulations of the present invention act in a multifunctional way in the fight against acne since they have proven antimicrobial, seborregulatory and anti-inflammatory action (minimizes the redness associated with acne lesions).
- the formulations of the present invention show greater efficacy results in reducing acne and/or reducing sebum and in less time than other products.
- the most innovative and expressive are related to sebum control, an action considered unprecedented/unexpected for the compositions of the present invention.
- formulations of plant origin obtained according to green chemistry precepts; no animal testing, vegan, in line with international sustainability standards to obtain products with the lowest environmental impact and chain traceability.
- the composition of the present invention is formed by the synergistic combination of glycols, fatty acids, polyols or sugar alcohols and/or esters and ethers derived from fatty acids and sugar alcohols.
- the present invention decreases the amount of xylitol (or its derivatives) needed to combat acne.
- the present invention presents several advantages (cited above) compared to known compositions comprising xylitol and derivatives.
- the present invention presents an antisebogenic composition
- an antisebogenic composition comprising: a) 10% to 50% by weight of at least one fatty acid with 3 to 22 carbons; b) 10% to 50% by weight of at least one polyol; c) 20% to 70% by weight of at least one glycol.
- the composition comprises from 20% to 50% by weight of glycol. In one embodiment, the composition comprises from 30% to 50% by weight of glycol. In one embodiment, the composition comprises from 25% to 50% by weight of glycol. In one embodiment, the composition comprises from 25% to 40% by weight of glycol. In one embodiment, the composition comprises from 30% to 40% by weight of glycol.
- the glycols are cyclic and/or linear C1-20 chain alkanediols (1 to 20 carbons) and/or C1-20 chain phenyl alcohols. In one embodiment, the glycols are cyclic and/or linear C1-16 chain alkanediols. In one embodiment, the glycols are cyclic and/or linear C1-12 chain alkanediols. In one embodiment, the glycols are cyclic and/or linear C1-10 chain alkanediols. In one embodiment, the glycols are alkanediols of chain C1 -08 cyclic and/or linear.
- the glycols are cyclic and/or linear C1-06 chain alkanediols.
- the glycol is 1,3-propanediol, pentylene glycol, hexanediol, caprylyl glycol, benzyl glycol, arachidyl glycol, butylene glycol, cetyl glycol, diethylene glycol, hexacosyl glycol, hexylene glycol, phenylpropanol, phenethyl alcohol, ethoxydiglycol or combinations thereof.
- the fatty acid has a chain of 6 to 20 carbons. In one embodiment, the fatty acid has a chain of 8 to 20 carbons. In one embodiment, the fatty acid has a chain of 3 to 15 carbons. In one embodiment, the fatty acid has a chain of 3 to 10 carbons. In one embodiment, the fatty acid has a chain of 6 to 15 carbons. In one embodiment, the fatty acid has a chain of 6 to 12 carbons.
- the fatty acid is selected from the group consisting of butyric acid, caprolic acid, caprylic acid, capric acid, stearic acid, palmitic acid, palmitoleic acid, lauric acid, myristic acid, myristoleic acid, isostearic acid, hydroxystearic acid, oleic acid, linolic acid, linolenic acid, ricinoleic acid, arachidic acid, arachidonic acid, behenic acid and erucic acid.
- the fatty acid is caprylic acid.
- the composition comprises from 15% to 45% by weight of fatty acid.
- the composition comprises from 20% to 40% by weight of fatty acid.
- the composition comprises from 25% to 40% by weight of fatty acid.
- the composition comprises from 25% to 35% by weight of fatty acid.
- the composition comprises from 25% to 30% by weight of fatty acid.
- the composition comprises from 20% to 50% by weight) polyol. In one embodiment, the composition comprises from 30% to 50% by weight polyol. In one embodiment, the composition comprises from 20% to 45% by weight polyol. In one embodiment, the composition comprises from 30% to 45% by weight polyol. In one embodiment, the polyols are cyclic and/or linear with 5 or more carbons or are derived from saccharide-type polyols. In one embodiment, the polyols are cyclic and/or linear have 6 or more carbons and/or are derived from disaccharide-type polyols.
- the polyol is xylitol, sorbitol, glycerol, mannitol, maltitol, Inositol, derivatives and/or combinations thereof.
- the esters and ethers derived from the association of fatty acids and polyols can be, more specifically, xylyl sesquicaprylate and anhydroxylitol.
- the present invention presents a cosmetic and/or pharmaceutical formulation comprising from 0.1% to 5.0% by weight of said antisebogenic composition and from 0.1% to 30% by weight of a vehicle cosmetically and/or pharmaceutically acceptable.
- the formulation comprises from 0.1% to 4.0% by weight of said antisebogenic composition. In one embodiment, the formulation comprises from 0.1% to 3.0% by weight of said antisebogenic composition. In one embodiment, the formulation comprises from 0.1% to 2.0% by weight of said antisebogenic composition. In one embodiment, the formulation comprises from 0.5% to 4.0% by weight of said antisebogenic composition. In one embodiment, the formulation comprises from 0.5% to 3.0% by weight of said antisebogenic composition. In one embodiment, the formulation comprises from 0.5% to 2.0% by weight of said antisebogenic composition. In one embodiment, the formulation comprises from 0.5% to 1.0% by weight of said antisebogenic composition.
- the cosmetically and/or pharmaceutically acceptable carrier is selected from the group consisting of suspending bases, antimicrobial agents, solubilizing agents, anti-acne agents, neutralizing agents, sensory modifiers, fragrances, dyes, pigments and combinations thereof.
- the formulation can be presented in the form of powders, creams, ointments, lotions, sprays, suspensions, gel, cream-gel, microemulsion, nanoemulsion, soap, soap, moisturizers, sunscreens, mask, oil, wipes, ointments.
- the formulation comprises from 0.1% to 15% by weight of a suspending base, the suspending base being a thickening agent, surfactants or emulsifiers. In one embodiment, the formulation comprises from 0.1% to 10% by weight of a suspending base. In one embodiment, the formulation comprises from 0.1% to 5% by weight of a suspending base. In one embodiment, the formulation comprises from 0.5% to 15% by weight of a suspending base. In one embodiment, the formulation comprises from 0.5% to 10% by weight of a suspending base. In one embodiment, the formulation comprises from 0.5% to 5% by weight of a suspending base.
- the suspending base is a thickening agent selected from the group consisting of sodium polyacrylate, sodium acryloyldimethyl taurate / sodium acrylate copolymer, carbomer, hydroxyethylcellulose, guar gum, xanthan gum, tara gum, acacia gum, or combinations thereof.
- the suspensor base is a surfactant.
- the surfactant is selected from the group consisting of sodium lauryl sarcosinate, cocamidopropyl betaine, lauryl glucoside, polysorbate 20, polysorbate 60, polysorbate 80, or combinations thereof.
- the formulation comprises 0.1% to 10.0% by weight of antimicrobial agents for preserving the formulation. In one embodiment, the formulation comprises 0.1% to 5.0% by weight of antimicrobial agents. In one embodiment, the formulation comprises 0.1% to 2.0% by weight of antimicrobial agents.
- the antimicrobial agent is benzyl alcohol, potassium sorbate or phenoxyethanol, caprylyl glycol, xylyl sesquicaprylate, sodium anisate, sodium levulinate, ethylhexylglycerin, or combinations thereof.
- the formulation comprises 0.10% to 30% by weight of active solubilizing agents.
- the solubilization is ethanol, propylene glycol, ethoxydiglycol, butylene glycol or glycerin.
- the formulation comprises 0.1% to 10% by weight of at least one neutralizing agent. In one embodiment, the formulation comprises 0.1% to 5% by weight of at least one neutralizing agent. In one embodiment, the neutralizing agent is selected from the group consisting of sodium hydroxide, potassium hydroxide, citric acid, arginine, triethanolamine, aminomethylpropanol, 3-amino, 1,2-propanediol, dimethylglucamine, or combinations thereof.
- the formulation comprises 0.1 to 10.0% by weight of classic anti-acne agents.
- the anti-acne agent is salicylic acid, benzoyl peroxide, sulfur, sodium sulfacetamide, alpha hydroxy acids (AHAs), niacinamide, retinoids, plant extracts or combinations thereof.
- the formulation comprises from 0.1% to 20% by weight of emollient. In one embodiment, the formulation comprises from 0.1% to 15% by weight of emollient. In one embodiment, the formulation comprises from 0.1% to 10% by weight of emollient.
- the emollient is selected from the group consisting of glycerin, propylene glycol, vegetable oils, fatty acid esters, or combinations thereof.
- the present invention presents the use of said antisebogenic composition in the preparation of a formulation for a dermatological and/or aesthetic method.
- the antisebogenic composition is used in the preparation of a medicament for treating acne. In one embodiment, the antisebogenic composition is used in preparing a formulation for treating skin oiliness. In one embodiment, the antisebogenic composition is used in the preparation of a skin aging treatment formulation; sebaceous hyperplasia; dermatosis; and seborrhea.
- the present invention presents a method of controlling oiliness in the skin, comprising the topical application of an antisebogenic composition as defined above.
- the antisebogenic composition is used in the preparation of a cosmetic and/or dermatological formulation.
- the formulation is pharmaceutical.
- the production process of the composition of the present patent application comprises the steps of: mixing the fatty acid with the polyol, under heating; neutralization; filtration; adding the glycol; stirring under heating; and filtration.
- the composition of the present invention (P19/7) can be used in a concentration range between 0.1% to 5.0% by weight, preferably between 0.5 to 1.0% by weight , applied in a cosmetic or pharmaceutical formulation suitable for human or veterinary use.
- the present invention provides a method of controlling acne. In one embodiment, the present invention features a method of modulating sebogenesis.
- a cosmetic or pharmaceutical formulation suitable for human or veterinary use means any and all types of solvents, dispersion media, encapsulations, permeation enhancing agents, surfactants, preservatives and other ingredients, alone or in combination, and which are physiologically compatible.
- compositions and formulations can be used as cosmetics or cosmeceuticals or adjuvant in pharmaceutical products for topical use, or even in products for veterinary use to control oiliness, control or treat acne or acne conditions.
- This list of applications includes oil control products, anti-acne products or acne treatment products, skin cleaning products, such as soaps, soaps, gels, lotions, micellar waters, make-up removers, etc., cosmetics for microbiota modulation and/or oiliness of the skin and scalp, astringent lotions, facial masks, exfoliating cosmetics, among others.
- the present invention presents a synergistic composition which, even at low concentrations in cosmetic and/or pharmaceutical formulations, presents high efficacy, stability, safety and compatibility with the skin.
- the components can be of vegetable origin, being a vegan, green and sustainable option.
- Minimum Inhibitory Concentration - MIC Minimum Inhibitory Concentration
- MIC is defined as the lowest concentration of an antimicrobial that inhibits the visible growth of a microorganism after incubation in a certain period of time. This study aimed to determine the ideal concentration to inhibit the visible growth of Cutibacterium acnes and Staphylococcus aureus.
- P19/7 had a MIC of 0.125% by weight for C. acnes (ATCC6919) and 0.250% by weight for S. aureus (ATCC6538).
- the Time-Kill kinetics test also known as “suspension test or suspension time elimination analysis”, determines the time required by a given concentration of antimicrobial agent to kill the microorganism.
- the main purpose of this test is to evaluate the microbial reduction of the test after being exposed to the antimicrobial agent.
- P19/7 at a concentration of 0.5% by weight and 1.0% by weight achieved the minimum expected reduction of 3-log in the microbial population from 1 minute of contact of the composition of the present invention with the target microorganism. There was no resumption of microbial growth until the end of the study, at 90 minutes.
- the purpose of the test was to evaluate the effects of P19/7 on the expression of 5-alpha reductase type 1 in cultured human keratinocytes.
- the enzyme 5-alpha-reductase (5a-DHT) acts in the conversion of testosterone into dihydrotestosterone (DHT), a steroid responsible for modulating sebaceous secretion.
- human keratinocytes obtained commercially were cultivated in specific culture media and kept in a humid incubator at 37 °C containing 5% CO2. When they reached confluence ( 3rd to 5th passage), cells were seeded into a 6-well plate and incubated with 0.0049% (w/v) P19/7 + Testosterone ( 1.10'8 mol/L) or Testosterone ( 1.10'8 mol/L) for a period of 24 hours. After 24 hours of incubation, the RNA was extracted using the PureLink RNA Mini Kit (Thermo Fisher) and quantified using the NanoDrop Lite spectrophotometer (Thermo Scientific).
- Tests were performed on a StepOnePlus device (Applied Byosystems).
- a commercially available analysis system was used (TaqMan® Gene Expression Assays; SRD5A1 : (HS00971643_G1 , 5-alpha reductase type 1 ); B2M: Hs00984230_m1 ; Applied Biosystems), with primers and probes based on the sequence consensus using the 1-Step TaqMan® RNA-to-CTTM Kit (Applied Byosystems).
- the B2M gene (beta-2-microglobulin) was used as a reference (endogenous).
- Gene expression of 5-alpha reductase was calculated according to Pfaffl (2001 ).
- the P19/7 composition was applied in a cosmetic base (BC) in a concentration of 0.5% by weight and 1% by weight and compared to a placebo base, without active ( Table 1 ).
- Porphyrins are secreted by C. acnes and, when exposed to UV light, absorb photons and pass to an excited singlet state, from which, when returning to the ground state, they emit fluorescence, allowing their quantification. For this reason, it is an excellent indicator of the presence of C. acnes.
- Figures 7 illustrates the most relevant results of the general appearance of the skin treated with P19/7 at 0.5% and 1.0% by weight for 28 days. Participant TR01 had improvement in the general aspects of the skin (erythema, edema, presence and size of acne) after 28 days of treatment with P19/7 at 0.5% by weight. Similar results were observed for participant TR022, treated with 1.0 wt% P19/7. Participant TR07, treated with P19/7 at 0.5% by weight, showed improvement in the acne size parameter for overall skin appearance.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22874004.9A EP4410270A1 (en) | 2021-10-01 | 2022-10-03 | Antisebogenic composition, formulation and use of the composition |
CN202280066162.8A CN118043025A (zh) | 2021-10-01 | 2022-10-03 | 抗皮脂生成组合物、制剂以及组合物的用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR1020210197560 | 2021-10-01 | ||
BR102021019756A BR102021019756A2 (pt) | 2021-10-01 | 2021-10-01 | Composição antissebogênica, formulação e uso da composição |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023049981A1 true WO2023049981A1 (pt) | 2023-04-06 |
Family
ID=85780305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BR2022/050387 WO2023049981A1 (pt) | 2021-10-01 | 2022-10-03 | Composição antissebogênica, formulação e uso da composição |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4410270A1 (pt) |
CN (1) | CN118043025A (pt) |
BR (1) | BR102021019756A2 (pt) |
WO (1) | WO2023049981A1 (pt) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2349698A1 (en) | 1998-11-03 | 2000-05-11 | Bristol-Myers Squibb Company | Skin moisturizer compositions containing a sebum control agent |
EP1050300B1 (en) | 1999-04-22 | 2004-08-04 | Shiseido Company Limited | Selective antibacterial composition |
US20090209604A1 (en) | 2008-02-14 | 2009-08-20 | Jerry Zhang | Topical combination therapy for treating acne |
WO2011047420A1 (en) | 2009-10-19 | 2011-04-28 | Chemeq Ltd | Cosmetic compositions |
EP2496215A2 (en) | 2009-11-03 | 2012-09-12 | Evocutis plc | Antimicrobial and anti-acne formulations |
WO2012151441A1 (en) | 2011-05-04 | 2012-11-08 | Lincoln Manufacturing Inc. | Natural antimicrobial compositions |
AU2012272804A1 (en) * | 2011-06-22 | 2014-01-16 | Vyome Therapeutics Limited | Conjugate-based antifungal and antibacterial prodrugs |
US8716506B2 (en) | 2008-10-20 | 2014-05-06 | Chemyunion Quimica Ltda. | Xylitol esters and ethers applied as alternative emulsifiers, solvents, co-emulsifiers and preservative systems for pharmaceutical and cosmetic products |
US8795693B2 (en) * | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US20180153177A1 (en) | 2014-03-10 | 2018-06-07 | The Trustees Of Columbia University In The City Of New York | Botanical antimicrobial compositions |
WO2018211333A1 (en) | 2017-05-19 | 2018-11-22 | Alumier Europe Limited | Preservative systems |
KR101939851B1 (ko) | 2013-10-01 | 2019-01-17 | 켐유니온 키미카 엘티디에이 | 화장품, 약제학 및 수의학 적용분야를 위한 항미생물, 공-유화제 및 증점제 특성을 가지는 자일리틸 에스테르 함유 조성물 |
-
2021
- 2021-10-01 BR BR102021019756A patent/BR102021019756A2/pt not_active Application Discontinuation
-
2022
- 2022-10-03 WO PCT/BR2022/050387 patent/WO2023049981A1/pt active Application Filing
- 2022-10-03 CN CN202280066162.8A patent/CN118043025A/zh active Pending
- 2022-10-03 EP EP22874004.9A patent/EP4410270A1/en active Pending
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2349698A1 (en) | 1998-11-03 | 2000-05-11 | Bristol-Myers Squibb Company | Skin moisturizer compositions containing a sebum control agent |
EP1050300B1 (en) | 1999-04-22 | 2004-08-04 | Shiseido Company Limited | Selective antibacterial composition |
US8795693B2 (en) * | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US20090209604A1 (en) | 2008-02-14 | 2009-08-20 | Jerry Zhang | Topical combination therapy for treating acne |
US8716506B2 (en) | 2008-10-20 | 2014-05-06 | Chemyunion Quimica Ltda. | Xylitol esters and ethers applied as alternative emulsifiers, solvents, co-emulsifiers and preservative systems for pharmaceutical and cosmetic products |
WO2011047420A1 (en) | 2009-10-19 | 2011-04-28 | Chemeq Ltd | Cosmetic compositions |
EP2496215A2 (en) | 2009-11-03 | 2012-09-12 | Evocutis plc | Antimicrobial and anti-acne formulations |
WO2012151441A1 (en) | 2011-05-04 | 2012-11-08 | Lincoln Manufacturing Inc. | Natural antimicrobial compositions |
AU2012272804A1 (en) * | 2011-06-22 | 2014-01-16 | Vyome Therapeutics Limited | Conjugate-based antifungal and antibacterial prodrugs |
KR101939851B1 (ko) | 2013-10-01 | 2019-01-17 | 켐유니온 키미카 엘티디에이 | 화장품, 약제학 및 수의학 적용분야를 위한 항미생물, 공-유화제 및 증점제 특성을 가지는 자일리틸 에스테르 함유 조성물 |
US20180153177A1 (en) | 2014-03-10 | 2018-06-07 | The Trustees Of Columbia University In The City Of New York | Botanical antimicrobial compositions |
WO2018211333A1 (en) | 2017-05-19 | 2018-11-22 | Alumier Europe Limited | Preservative systems |
Non-Patent Citations (3)
Title |
---|
ANONYMOUS: "DISCOVER HYGEAPHOS®", FARMACOTÉCNICA, 1 April 2017 (2017-04-01), XP093056870, Retrieved from the Internet <URL:https://farmacotecnica.com.br/conheca-o-hygeaphos> [retrieved on 20230622] * |
ANONYMOUS: "INTENSIVE TREATMENT TONIC AGAINST DANDRUFF - LUMINA - 100ML Product No. 107168", NATURA, 1 January 2023 (2023-01-01), XP093056863, Retrieved from the Internet <URL:https://www.naturabrasil.fr/pt-pt/cabelo/t%C3%93nico-de-tratamento-intensivo-contra-a-caspa-107168> [retrieved on 20230622] * |
GENRICH FLORIAN, KOCH CHRISTIN, MASSIRONI MICHELE, THOMAZ FERNANDA: "Propanediol Caprylate: Shifting the Microbiome, Sebum Levels and Classic Approach to Dandruff", COSMETICS&TOILETRIES, 1 June 2021 (2021-06-01), XP093056860, Retrieved from the Internet <URL:https://www.cosmeticsandtoiletries.com/testing/article/21836364/symrise-propanediol-caprylate-shifting-the-microbiome-sebum-levels-and-classic-approach-to-dandruff> [retrieved on 20230622] * |
Also Published As
Publication number | Publication date |
---|---|
EP4410270A1 (en) | 2024-08-07 |
CN118043025A (zh) | 2024-05-14 |
BR102021019756A2 (pt) | 2023-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8313782B2 (en) | Acne vulgaris treatment regimen | |
SA515360423B1 (ar) | تركيبة غسول مستحلب بيروكسيد بنزويل (bpo) | |
WO1999059580A1 (fr) | Agents preventifs/therapeutiques pour les affections cutanees | |
JP2006348035A (ja) | 外用に適する組成物 | |
EP4248981A2 (en) | Formulations containing pomegranate seed oil, rosa canina fruit oil and inula viscosa oleoresin or extract | |
US20050137164A1 (en) | Diclofenac compositions for the treatment of skin disorders | |
EA011723B1 (ru) | Композиции для местного применения | |
WO2012131347A1 (en) | Usnic acid topical formulation | |
KR20080070621A (ko) | 신규 피부 관리 조성물 | |
ES2689070T3 (es) | Composición farmacéutica tópica, método para producir la composición farmacéutica tópica, uso de la composición farmacéutica tópica y método para el tratamiento tópico de psoriasis, dermatitis atópica o eczema crónico | |
WO2013050959A1 (en) | Composition for the treatment of skin lesions | |
KR20030005174A (ko) | 하이드록시테트론산을 함유하는 피부 미백제 | |
EP3378475B1 (en) | Composition and kit for the use in the prevention of recurrent onychomycosis | |
US11918547B2 (en) | Bakuchiol compositions for treatment of post inflammatory hyperpigmentation | |
JP2006193492A (ja) | コエンザイムq10、アスコルビン酸誘導体及びビタミンkなどを有効成分とする口唇用化粧料 | |
EP4410270A1 (en) | Antisebogenic composition, formulation and use of the composition | |
WO2005007071A2 (en) | Skin formulation | |
KR20110138709A (ko) | 5-아미노레불린산 또는 이의 에스테르를 포함하는 여드름 개선용 조성물 | |
BR102022019970A2 (pt) | Composição antissebogênica, formulação e uso da composição | |
CA2762394C (en) | Topical retinoid solutions | |
PT2011504E (pt) | Agente dermatológico para o tratamento e/ou de cuidados da pele nos casos de dermatite atópica | |
JP5746807B2 (ja) | 皮膚用化粧品の組成物 | |
EP1663195B1 (en) | Taurine bromamine for inhibiting pathogenic bacteria and fungi growth as well as in a microbicidal composition | |
WO2012172318A1 (en) | Formulations containing tropolonoids, copper salt and a solvent system | |
EP3490577B1 (en) | Skin compositions comprising turmerones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22874004 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18694077 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280066162.8 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022874004 Country of ref document: EP Effective date: 20240502 |